Fusobacterium Nucleatum Promotes Microsatellite Instability in Colorectal Carcinoma Through Up-regulation of miRNA-155-5p-Targeted Inhibition of MSH6 via the TLR4/NF-κB Signaling Pathway
- PMID: 39334517
- DOI: 10.1002/adbi.202400293
Fusobacterium Nucleatum Promotes Microsatellite Instability in Colorectal Carcinoma Through Up-regulation of miRNA-155-5p-Targeted Inhibition of MSH6 via the TLR4/NF-κB Signaling Pathway
Abstract
Fusobacterium nucleatum (Fn) is significantly associated with poor prognosis in colorectal carcinoma (CRC), however, mechanisms of Fn in DNA mismatch repair (MMR) and microsatellite instability (MSI) in CRC have not been fully elucidated. Clinical samples are collected to analyze the relationship between Fn abundance and microsatellite stability. Tumor cells are treated with Fn to detect the expression of proteins related to toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (Myd88), mutS homolog 6 (MSH6), and nuclear factor-κB (NF-κB) signaling pathways, respectively. Combined with the prediction results from TargetScan, the regulatory role of microRNA upstream of MSH6 is demonstrated. The effect of this regulatory axis on CRC development is demonstrated using a nude mouse tumor model. Compared with microsatellite stability (MSS)-type CRC patients, MSI-type showed higher Fn abundance. Fn treatment of CRC cells activated TLR4/Myd88/NF-κB signaling pathway, transcriptionally activating miRNA-155-5p expression, thereby negatively regulating MSH6. Fn treatment accelerated the malignant progression of CRC in mice, and this process is inhibited by miRNA-155-5p antagomir. Fn in CRC upregulated miRNA-155-5p by activating TLR4/NF-κB signaling to inhibit MSH6, and this regulatory pathway may affect MSS of cancer cells.
Keywords: DNA mismatch repair; Fusobacterium nucleatum; colorectal carcinoma; microRNA; microsatellite instability.
© 2024 Wiley‐VCH GmbH.
Similar articles
-
Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.Gastroenterology. 2017 Mar;152(4):851-866.e24. doi: 10.1053/j.gastro.2016.11.018. Epub 2016 Nov 19. Gastroenterology. 2017. PMID: 27876571 Free PMC article.
-
Fusobacterium nucleatum impairs DNA mismatch repair and stability in patients with squamous cell carcinoma of the head and neck.Cancer. 2022 Sep 1;128(17):3170-3184. doi: 10.1002/cncr.34338. Epub 2022 Jul 5. Cancer. 2022. PMID: 35789992
-
Fusobacterium nucleatum Facilitates M2 Macrophage Polarization and Colorectal Carcinoma Progression by Activating TLR4/NF-κB/S100A9 Cascade.Front Immunol. 2021 May 21;12:658681. doi: 10.3389/fimmu.2021.658681. eCollection 2021. Front Immunol. 2021. PMID: 34093546 Free PMC article.
-
Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.World J Gastroenterol. 2016 Jan 14;22(2):557-66. doi: 10.3748/wjg.v22.i2.557. World J Gastroenterol. 2016. PMID: 26811607 Free PMC article. Review.
-
Fusobacterium nucleatum modulates the Wnt/β-catenin pathway in colorectal cancer development.Int J Biol Macromol. 2025 Apr;299:140196. doi: 10.1016/j.ijbiomac.2025.140196. Epub 2025 Jan 21. Int J Biol Macromol. 2025. PMID: 39848378 Review.
Cited by
-
Gut microbiota in gastric cancer: from pathogenesis to precision medicine.Front Microbiol. 2025 Jul 30;16:1606924. doi: 10.3389/fmicb.2025.1606924. eCollection 2025. Front Microbiol. 2025. PMID: 40809053 Free PMC article. Review.
-
The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review.BMC Gastroenterol. 2025 May 16;25(1):380. doi: 10.1186/s12876-025-03968-y. BMC Gastroenterol. 2025. PMID: 40380157 Free PMC article. Review.
References
-
- K. Thanikachalam, G. Khan, Nutrients 2019, 11, 164.
-
- Y. Xi, P. Xu, Transl. Oncol. 2021, 14, 101174.
-
- R. L. Siegel, N. S. Wagle, A. Cercek, R. A. Smith, CA Cancer J. Clin. 2023, 73, 233.
-
- N. A. Johdi, N. F. Sukor, Front. Immunol. 2020, 11, 1624.
-
- A. Marabelle, D. T. Le, P. A. Ascierto, A. M. Di Giacomo, A. De Jesus‐Acosta, J. P. Delord, R. Geva, M. Gottfried, N. Penel, A. R. Hansen, S. A. Piha‐Paul, T. Doi, B. o. Gao, H. C. Chung, J. Lopez‐Martin, Y. J. Bang, R. S. Frommer, M. Shah, R. Ghori, A. K. Joe, S. K. Pruitt, L. A. Diaz Jr, J. Clin. Oncol. 2020, 38, 1.
MeSH terms
Substances
Grants and funding
- [2022]884/Fujian Health Medicine and Politics
- Key Clinical Specialty Discipline Construction Program of Fujian, P.R.C
- 2022BD1601/The special funds project of the Second Affiliated Hospital of Fujian Medical University
- 2022BD1602/The special funds project of the Second Affiliated Hospital of Fujian Medical University
- 320.6750.2023-19-20/Wu Jieping Medical Foundation
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous